Richard F. Bergstrom

TL;DR: Multicentre trials in patients with schizophrenia confirm that olanzapine is a novel antipsychotic agent with broad efficacy, eliciting a response in both the positive and negative symptoms of schizophrenia, and dosage modification should be considered for patients characterised by a combination of factors associated with decreased oxidative metabolism.

TL;DR: Pharmacokinetics of fluoxetine in the elderly and normal volunteers appear to be similar and pharmacokinetic analyses in patients with varying degrees of renal impairment did not show significant differences from healthy subjects.

TL;DR: Olanzapine long-acting injection was efficacious in maintenance treatment of schizophrenia for up to 24 weeks, with a safety profile similar to oral olanzapine except for injection-related adverse events, and the three standard long- acting doses were superior to the very low reference dose based on time to exacerbation.

TL;DR: Patient demographic characteristics found to influence the pharmacokinetics of duloxetine include sex, smoking status, age, ethnicity, cytochrome P450 (CYP) 2D6 genotype, hepatic function and renal function, and pharmacokinetic results from drug interaction studies show that activated charcoal decreases dulxetine exposure, and that CYP1A2 inhibition increases dul oxetine Exposure to a clinically significant degree.

TL;DR: The findings indicate that fluoxetine causes an inhibition of tricyclic 2‐hydroxylation and may decrease first‐pass and systemic metabolism and a lower dosage may be needed to maintain steady‐state concentrations and to avoid undesirable side effects caused by excessive tricyClic concentrations.